about
michGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsGranulopoiesis-stimulating factors for preventing infections after autologous peripheral stem cell transplantation for lymphoma and multiple myeloma in adultsNew developments in the treatment of chemotherapy-induced neutropenia: focus on balugrastimExercise as an Adjuvant Therapy for Hematopoietic Stem Cell MobilizationDesign Rationale and Development Approach for Pegfilgrastim as a Long-Acting Granulocyte Colony-Stimulating FactorChemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.Development of Romiplostim for Treatment of Primary Immune Thrombocytopenia From a Pharmacokinetic and Pharmacodynamic Perspective.A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy.PEGylation enables the specific tumor accumulation of a peptide identified by phage display.Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapyA Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and DocetaxelRomiplostim dose-response in patients with myelodysplastic syndromesConfirmation of Biosimilarity in a Pharmacokinetic/Pharmacodynamic Study in Healthy Volunteers for an Analytically Highly Similar Pegfilgrastim.Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.Prevention of chemotherapy-induced neutropenia with pegfilgrastim: pharmacokinetics and patient outcomes.Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.Granulocyte colony-stimulating factor (GCSF) fused with Fc Domain produced from E. coli is less effective than Polyethylene Glycol-conjugated GCSF.Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial.Role of the methoxy group in immune responses to mPEG-protein conjugates.Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.Genetic background influences susceptibility to chemotherapy-induced hematotoxicity.A phase I study of different doses and frequencies of pegylated recombinant human granulocyte-colony stimulating factor (PEG rhG-CSF) in patients with standard-dose chemotherapy-induced neutropenia.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy.Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe.
P2860
Q24186266-A796EDA5-998B-4DC4-82F8-0C1D5D4A57CBQ24200850-E1AFF25A-F1B6-495D-A43E-4AFA14E1F425Q26738509-67EF9A4E-471F-496B-8E22-E49622C5B913Q26749247-67628A43-A3C4-4DC8-B76D-6568A0244454Q27004054-E60C054C-36BF-406A-85B0-F8C382782907Q30975418-353B47D1-594C-447B-B4F8-438C45D906E5Q33420907-78D0CF67-D65F-4EA7-BDA0-5D090D3A21ABQ33431320-264F5F50-9CCA-4504-85C6-188F7ECCCEEFQ34333814-0BB2044D-0019-4DBB-9E57-E2AC7FC61C4BQ34615563-29061B2D-8D5D-4784-A119-BA3CC43BB5F4Q34941030-6B121A9C-7D32-4032-BF15-8E220FBD82FCQ36452230-4692267C-563A-47D5-B15D-457BE30D3989Q36948110-18AE69F2-2CA5-495E-BC45-7A5B43252A41Q37391741-080AD701-D225-43C6-B180-D257564FECDAQ38060204-5EEF9743-7F1D-465B-A0B5-F49BDC8FA65EQ38072290-F422B545-A5D7-443D-B484-B9EA4C23C121Q38126361-82B554A4-E598-4CBC-B471-5ED8D157F194Q38269589-18D87AF0-CDD5-4439-A7D0-C34DF418F6AFQ38613025-E08F86F3-2938-40FF-B297-06E261A0FE2DQ38696361-B454EB48-EEE0-4E7A-A8C0-8661CC0921F0Q39698919-2BA6BBA2-029A-4B67-816D-D6B49C400A49Q41453238-C4DBE041-0197-4683-A311-195CB7A44FF9Q41940240-842F85E2-DC10-4657-A051-F2EFAA5D5FADQ44019603-CBBF5ACA-A354-4126-AA25-1A8FCD15C7ADQ47094464-03EBD7D9-70B8-4791-B492-8710B1A672A5Q47106934-C378FD50-0079-49C9-AF91-ED4FBC37E142Q50878372-74995DB7-DBA2-401C-99DD-CB99D1F5ACDBQ53172587-C40B15A7-8C38-4ABC-B1D0-19D339727C1CQ53534502-8EE558A0-1E56-47F6-A837-4955BCEE1C2D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
@en
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
@nl
type
label
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
@en
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
@nl
prefLabel
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
@en
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
@nl
P2860
P1476
Pharmacokinetics and pharmacodynamics of pegfilgrastim.
@en
P2093
Bing-Bing Yang
P2860
P304
P356
10.2165/11586040-000000000-00000
P577
2011-05-01T00:00:00Z